AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Back to search results

Microbiome Based Treatment for Cirrhosis Patients

Detailed Technology Description
Cirrhosis is a major cause of death/disability worldwide and the eighth leading cause of death in the US in 2010. Cirrhosis patients have a high likelihood of multiple hospitalizations and developing infections. One major reason is related to dysbiosis or unfavorable microbiome of the gut. Overuse of antibiotics in cirrhosis results in increase of culture-negative and fungal infections from dysbiosis.
*Abstract

From a patient’s microbiome sample screening (16S rRNA bacterial) we can predict which patients:

  • have fungal overgrowth requiring a lower threshold for anti-fungal coverage
  • are unlikely to sustain further antibiotic use
  • are likely to need repletion of their microbiome using:
    • probiotics
    • prebiotics
    • fecal microbial transplant
  • are expected to get re-hospitalized within 90 days
  • to treat with antibiotics or antifungal agents

Clinical Trials: 169 patients, over 90% accuracy identifying/predicting infections
Country/Region
USA

For more information, please click Here
Mobile Device